Aimmune Therapeutics (AIMT) Earns News Sentiment Rating of 0.15

News coverage about Aimmune Therapeutics (NASDAQ:AIMT) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aimmune Therapeutics earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.195093191156 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the media headlines that may have impacted Accern Sentiment’s analysis:

Several analysts recently commented on the stock. Wedbush restated a “buy” rating on shares of Aimmune Therapeutics in a report on Friday, February 23rd. BidaskClub cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, February 22nd. Piper Jaffray set a $62.00 target price on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research note on Thursday, April 5th. Credit Suisse Group set a $47.00 target price on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 10th. Finally, Zacks Investment Research cut shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 11th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Aimmune Therapeutics presently has a consensus rating of “Buy” and an average target price of $57.22.

Aimmune Therapeutics opened at $29.96 on Thursday, according to MarketBeat. The company has a market capitalization of $1.73 billion, a price-to-earnings ratio of -11.48 and a beta of -0.36. Aimmune Therapeutics has a 12-month low of $29.62 and a 12-month high of $30.28.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.21). During the same quarter in the previous year, the business posted ($0.52) EPS. equities research analysts predict that Aimmune Therapeutics will post -2.81 EPS for the current fiscal year.

In other news, insider Mary M. Rozenman sold 1,807 shares of Aimmune Therapeutics stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $33.10, for a total value of $59,811.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Douglas T. Sheehy sold 3,523 shares of Aimmune Therapeutics stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $36.52, for a total transaction of $128,659.96. Following the completion of the transaction, the insider now directly owns 32,500 shares in the company, valued at approximately $1,186,900. The disclosure for this sale can be found here. In the last three months, insiders bought 58,093 shares of company stock worth $1,858,976. Insiders own 24.56% of the company’s stock.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply